Upregulation of miR-489-3p and miR-630 inhibits oxaliplatin uptake in renal cell carcinoma by targeting OCT2.
10.1016/j.apsb.2019.01.002
- Author:
Lu CHEN
1
;
Le CHEN
1
;
Zhiyuan QIN
1
;
Jinxiu LEI
1
;
Sheng YE
2
;
Kui ZENG
1
;
Hua WANG
3
;
Meidan YING
1
;
Jianqing GAO
1
;
Su ZENG
1
;
Lushan YU
1
Author Information
1. Institute of Drug Metabolism and Pharmaceutical Analysis, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
2. Paediatric Intensive Care Unit, the Children׳s Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.
3. Department of Urology, Cancer Hospital of Zhejiang Province, Hangzhou 310022, China.
- Publication Type:Journal Article
- Keywords:
Epigenetic regulation;
OCT2;
Oxaliplatin;
Renal cell carcinoma;
miRNA
- From:
Acta Pharmaceutica Sinica B
2019;9(5):1008-1020
- CountryChina
- Language:English
-
Abstract:
Renal cell carcinoma (RCC) is one of the most common malignant tumors affecting the urogenital system, accounting for 90% of renal malignancies. Traditional chemotherapy options are often the front-line choice of regimen in the treatment of patients with RCC, but responses may be modest or limited due to resistance of the tumor to anticarcinogen. Downregulated expression of organic cation transporter OCT2 is a possible mechanism underlying oxaliplatin resistance in RCC treatment. In this study, we observed that miR-489-3p and miR-630 suppress OCT2 expression by directly binding to the OCT2 3'-UTR. Meanwhile, 786-O-OCT2-miRNAs stable expression cell models, we found that miRNAs could repress the classic substrate 1-methyl-4-phenylpyridinium (MPP), fluorogenic substrate ,-dimethyl-4-(2-pyridin-4-ylethenyl) aniline (ASP), and oxaliplatin uptake by OCT2 both and in xenografts. In 33 clinical samples, miR-489-3p and miR-630 were significantly upregulated in RCC, negatively correlating with the OCT2 expression level compared to that in adjacent normal tissues, using tissue microarray analysis and qPCR validation. The increased binding of c-Myc to the promoter of pri-miR-630, responsible for the upregulation of miR-630 in RCC, was further evidenced by chromatin immunoprecipitation and dual-luciferase reporter assay. Overall, this study indicated that miR-489-3p and miR-630 function as oncotherapy-obstructing microRNAs by directly targeting OCT2 in RCC.
